The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
- Conditions
- High Grade GliomaGlioblastomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma
- Interventions
- Drug: Regadensoson 0.1mgDrug: Regadensoson 0.2mgDrug: Regadensoson 0.4mgDrug: Regadensoson 0.7mgDrug: Regadensoson 1.0mgDrug: Regadensoson 1.4mg
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-10-06
- Target Recruit Count
- 7
- Registration Number
- NCT03971734
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Drug: BGB 324 (after surgery)Drug: BGB 324 (before surgery)
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2024-02-08
- Target Recruit Count
- 10
- Registration Number
- NCT03965494
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 16
- Registration Number
- NCT03961971
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Stanford University, Stanford, California, United States
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
- Conditions
- Mesothelioma
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 30
- Registration Number
- NCT03918252
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine, Baltimore, Maryland, United States
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
- Conditions
- Recurrent GlioblastomaIDH2 MutationRecurrent WHO Grade III GliomaIDH1 MutationRecurrent WHO Grade II Glioma
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-01-14
- Target Recruit Count
- 67
- Registration Number
- NCT03914742
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
- Conditions
- Bladder CancerNMIBCNon-Muscle Invasive Bladder CancerUrothelial Carcinoma Recurrent
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 43
- Registration Number
- NCT03914794
- Locations
- 🇺🇸
Associated Medical Professionals Urology, Syracuse, New York, United States
🇺🇸Midlantic Urology, Bala-Cynwyd, Pennsylvania, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
- Conditions
- MalignancyNeuropathyChemotherapy-induced Peripheral NeuropathyNeuropathies SensoryCancerMalignant Neoplasm
- Interventions
- Device: Neurosensory testing with Pressure-Specified Sensory Device
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-11-27
- Target Recruit Count
- 26
- Registration Number
- NCT03909464
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2021-10-15
- Target Recruit Count
- 7
- Registration Number
- NCT03886493
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
- Conditions
- Head and Neck Cancer MetastaticHead and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 26
- Registration Number
- NCT03878979
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2025-03-04
- Target Recruit Count
- 35
- Registration Number
- NCT03875287
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States